Tilray Brands (TLRY) Q2 2025 Earnings Call Transcript
Thank you for joining us for today's conference call to discuss Tilray Brands' financial results for the second quarter ended November 30th, 2024. All
Tilray Brands Reports Q2 2025 Financial Results
Year, Reaching $61 Million in Q2 with Growth Across All Four Business Segments. Achieved 9% Year-Over-Year Growth, Generating Record Q2 Net
Tilray Brands Posts Net Loss Of $85 Million In Q2 2025
Tilray Brands (TSX: TLRY) this morning reported its second quarter financial results, posting topline revenue of $211 million for the three month period ended November 30, 2024. “In our
Tilray Brands 2Q Loss Widens as Beverages Revenue Rises
Tilray Brands logged a wider loss in its fiscal second quarter and said revenue rose after sales at its beverage business offset declines at its core cannabis unit The cannabis-lifestyle and consumer-packaged-goods company on Friday posted a net loss for the three months ended Nov.
Tilray Reports Growth in Q2 2025 Amid Losses
Tilray ( (TLRY) ) has released its Q2 earnings. Here is a breakdown of the information Tilray presented to its investors.Stay Ahead of the
Tilray slips after Q2 FY25 revenue miss
Tilray Brands (NASDAQ:TLRY) traded ~8% lower in the premarket on Friday after the Canadian cannabis company fell short of Street forecasts for its Q2 FY25 revenue, despite exceeding expectations with its bottom line and FY25 outlook.
Tilray Brands, Inc. (TLRY) Reports Q2 Loss, Misses Revenue Estimates
Tilray Brands, Inc. (TLRY) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.
Business Insider1mon
Tilray Medical Launches its First Commercial “Grown in Germany” Medical Cannabis Products Under its Newly Expanded Cultivation License
This launch marks the first medical cannabis products to be grown in Germany by Aphria RX under the newly issued medical cannabis cultivation license under MedCanG. On July 15, 2024, Tilray ...
Mena FN5d
Medical Marijuana Market Set To Witness Significant Growth By 2024-2031: Tilray, Aphria, Inc., Vantage Hemp
Medical Marijuana Market is estimated to be valued at USD 22.34 Bn in 2024 and is expected to reach USD 56.27 Bn by 2031, exhibiting a CAGR of 14.1%. BURLINGAME, CA, UNITED STATES, January 6, 2025 ...
US Delta-9 THC Markets And German Medical Cannabis Synergize Tilray's Potential
Tilray Brands has expanded its US (Beer / Delta-9 THC) and German operations (Medical Cannabis). Find out why I continue my ...
Yahoo Finance3d
Tilray Medical Wins Tender to Supply Luxembourg with Medical Cannabis
Tilray Brands, Inc. NEUMÜNSTER, Germany, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), proudly announces that its German ...